KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $96.4 million.

  • Biomarin Pharmaceutical's Depreciation & Amortization (CF) fell 2.73% to $18.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.7 million, marking a year-over-year decrease of 17.01%. This contributed to the annual value of $96.4 million for FY2024, which is 7.63% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Depreciation & Amortization (CF) of $96.4 million as of FY2024, which was down 7.63% from $104.4 million recorded in FY2023.
  • Biomarin Pharmaceutical's Depreciation & Amortization (CF)'s 5-year high stood at $108.0 million during FY2021, with a 5-year trough of $96.4 million in FY2024.
  • Its 3-year average for Depreciation & Amortization (CF) is $100.9 million, with a median of $102.0 million in 2022.
  • In the last 5 years, Biomarin Pharmaceutical's Depreciation & Amortization (CF) grew by 2.73% in 2021 and then declined by 7.63% in 2024.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Depreciation & Amortization (CF) stood at $105.2 million in 2020, then climbed by 2.73% to $108.0 million in 2021, then declined by 5.62% to $102.0 million in 2022, then climbed by 2.37% to $104.4 million in 2023, then fell by 7.63% to $96.4 million in 2024.